{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:10:58Z","timestamp":1761059458947},"reference-count":3,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/coc.0b013e3182546a91","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T08:15:53Z","timestamp":1355386553000},"page":"450-454","source":"Crossref","is-referenced-by-count":7,"title":["Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma"],"prefix":"10.1097","volume":"36","author":[{"given":"Stephen L.","family":"Richey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pheroze","family":"Tamboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaan S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita D.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance C.","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1023\/A:1008379101017","article-title":"Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.","volume":"11","author":"Adjei","year":"2000","journal-title":"Ann Oncol"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.0006-341X.2002.00089.x","article-title":"Monitoring the rates of composite events with censored data in phase II clinical trials.","volume":"58","author":"Cheung","year":"2002","journal-title":"Biometrics"},{"key":"R29-5-20210128","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma.","volume":"163","author":"Motzer","year":"2000","journal-title":"J Urol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e3182546a91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:08:20Z","timestamp":1620950900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201310000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":3,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3182546a91","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}